Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.57 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1306000 | 0.86 | OPRM1 (0.61) | ACHESIGMAR1 | |
| SCHEMBL3936632 | 0.84 | MCHR1 (0.69) | ACHEMCHR1CCR3SIGMAR1KMT2A | |
| SCHEMBL3143516 | 0.82 | MCHR1 (0.45) | ACHEMCHR1CCR3SIGMAR1KMT2A | |
| SCHEMBL5709408 | 0.82 | ACHE (0.59) | ACHEMCHR1CCR3SIGMAR1KMT2A | |
| SCHEMBL1062230 | 0.82 | OPRM1 (0.56) | ACHESIGMAR1 | |
| SCHEMBL1921490 | 0.81 | SIGMAR1 (0.56) | ACHECCR3SIGMAR1KMT2AMEN1 | |
| SCHEMBL10893210 | 0.81 | CHRM2 (0.56) | ACHESIGMAR1KMT2AMEN1 | |
| SCHEMBL5672524 | 0.81 | SIGMAR1 (0.50) | ACHECCR3SIGMAR1 | |
| SCHEMBL1207106 | 0.80 | OPRM1 (0.54) | ACHESIGMAR1 | |
| SCHEMBL2796219 | 0.80 | UBE2M (0.54) | ACHEMCHR1SIGMAR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | ACHE 2862/4885MCHR1 138/4885CCR3 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.